Calcitonin collaboration to end

Published: 28-May-2001


Pfizer is to terminate its oral calcitonin licence agreement with Unigene Laboratories after Phase I/II trial results did not meet its expectations. Unigene is now in discussions with other companies over licensing the development rights to the formulation.

You may also like